查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1951908

个人化医疗市场分析及预测（至2035年）：按类型、产品、服务、技术、应用、最终用户、组件、设备、流程和解决方案划分

Personalized Medicine Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Component, Device, Process, Solutions
出版日期: | 出版商: Global Insight Services | 英文 390 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计到2034年，个人化医疗市场规模将从2024年的5,651亿美元成长至1,1,274亿美元，年复合成长率约为8.4%。个人化医疗市场涵盖根据个人基因谱、生活方式和环境量身定制的医疗保健解决方案，从而实现精准治疗。该市场利用基因组学、诊断技术和数据分析来优化治疗效果。对标靶治疗的需求不断增长以及生物技术的进步正在推动市场成长，并促进药物研发、诊断技术和患者照护策略的创新。

个人化医疗市场正经历强劲成长，这主要得益于基因组学和生物技术的进步。治疗药物领域成长最为迅猛，这主要得益于标靶治疗和生物製药的普及，它们能够提供个人化的治疗方案；其次是伴随诊断，它能够实现精准的患者分层和监测。在治疗药物领域，肿瘤学占据主导地位，受益于个人化癌症治疗，患者预后得到显着改善。循环系统和神经系统疾病领域的应用也呈现成长势头，反映出人们对个人化医疗的日益关注。成长速度第二快的领域是个人化营养和健康，随着消费者寻求客製化的健康解决方案，该领域持续扩张。营养基因组学和基于微生物组的产品处于领先地位，提供个人化的饮食建议和补充剂。基因检测服务也不断发展，能够深入了解个体的健康风险和易感性。人工智慧和巨量资料分析的融合进一步推动了个人化医疗解决方案的发展，并促进了整个市场的创新和效率提升。

市场区隔
类型 治疗和诊断药物
产品 药物基因体学、伴随诊断、标靶治疗药物、基因检测套组
服务 基因测序、分子诊断服务、个人化医疗咨询
科技 次世代定序、聚合酵素链锁反应、生物资讯学、基因编辑
应用领域 肿瘤科、心臟科、神经科、感染疾病、呼吸系统疾病科
最终用户 医院、诊所、学术研究机构、製药公司
成分 软体、硬体和服务
装置 穿戴式装置、照护现场设备、实验室设备
流程 生物标记发现、药物开发和临床试验
解决方案 整合平台、独立解决方案、客製化解决方案

在个人化医疗市场，创新产品的推出和策略定价策略正在塑造市场份额的趋势。各公司正专注于以精准医疗为基础的治疗方法，从而形成由技术进步驱动的竞争格局。对个人化治疗方案的需求正在迅速增长，尤其是在肿瘤和罕见疾病领域。这一趋势促使製药公司加强研发投入，并培育创新文化。因此，市场正朝着更具针对性和有效性的治疗方案转变，从而改善患者预后并推动产业成长。竞争标竿研究表明，主要参与者正透过先进的基因组学和生物资讯技术加强差异化。监管影响，特别是美国和欧洲的严格指导方针，对于确保安全性和有效性以及塑造市场走向至关重要。监管环境在促进创新的同时，也维持高标准。市场分析表明，技术整合和策略联盟将推动市场强劲成长。数位健康技术和个人化诊断提供了充满希望的机会，增强了市场动力。儘管高成本和监管复杂性等挑战依然存在，但变革医疗保健的解决方案潜力巨大。

主要趋势和驱动因素：

基因组学和生物技术的进步正推动个人化医疗市场强劲成长。人工智慧 (AI) 和机器学习在药物研发和诊断中的应用是关键趋势。这些技术能够识别生物标记并制定个人化治疗方案，从而改善患者预后。另一个趋势是，由于慢性病发病率上升以及对更有效治疗方法的需求，标靶治疗的需求日益增长。个人化医疗提供了一种量身定制的治疗方案，可以提高疗效并减少副作用。监管机构也发挥重要作用，支持精准医疗倡议，进一步加速市场成长。此外，消费者基因检测服务的扩展使个人能够做出明智的健康决策。伴随诊断的日益普及也促进了这一趋势，有助于选择合适的治疗方法。数位健康科技与个人化医疗的融合为创新和病人参与创造了新的机会，为市场的持续扩张奠定了基础。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 治疗
    • 诊断
  • 市场规模及预测：依产品划分
    • 药物基因组学
    • 伴随诊断
    • 标靶治疗药物
    • 基因检测套组
  • 市场规模及预测：依服务划分
    • 基因测序
    • 分子诊断服务
    • 关于个人化医疗的咨询
  • 市场规模及预测：依技术划分
    • 次世代定序
    • 聚合酵素链锁反应
    • 生物资讯学
    • 基因编辑
  • 市场规模及预测：依应用领域划分
    • 肿瘤学
    • 心臟病学
    • 神经病学
    • 感染疾病
    • 呼吸系统疾病
  • 市场规模及预测：依最终用户划分
    • 医院
    • 诊所
    • 学术研究机构
    • 製药公司
  • 市场规模及预测：依组件划分
    • 软体
    • 硬体
    • 服务
  • 市场规模及预测：依设备划分
    • 穿戴式装置
    • 即时检测设备
    • 检测设备
  • 市场规模及预测：依製程划分
    • 生物标记发现
    • 药物研发
    • 临床试验
  • 市场规模及预测：按解决方案划分
    • 整合平台
    • 独立解决方案
    • 客製化解决方案

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 其他亚太地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • Illumina
  • Qiagen
  • Myriad Genetics
  • Genomic Health
  • Natera
  • Foundation Medicine
  • Adaptive Biotechnologies
  • Guardant Health
  • Invitae
  • Personalis
  • Care Dx
  • Blueprint Medicines
  • Blueprint Genetics
  • Grail
  • Freenome
  • Sema4
  • Tempus
  • Caris Life Sciences
  • Neo Genomics
  • Syapse

第九章：关于我们

简介目录
Product Code: GIS21446

Personalized Medicine Market is anticipated to expand from $565.1 billion in 2024 to $1,127.4 billion by 2034, growing at a CAGR of approximately 8.4%. The Personalized Medicine Market encompasses healthcare solutions tailored to individual genetic profiles, lifestyle, and environment, enabling precise medical treatment. This market leverages genomics, diagnostics, and data analytics to optimize therapeutic outcomes. Rising demand for targeted therapies and advancements in biotechnology are propelling growth, fostering innovations in drug development, diagnostics, and patient care strategies.

The Personalized Medicine Market is experiencing robust growth, propelled by advancements in genomics and biotechnology. The therapeutics segment is the top performer, driven by targeted therapies and biologics, which offer tailored treatment options. Companion diagnostics follow closely, enabling precise patient stratification and monitoring. Within the therapeutics segment, oncology holds the leading position, benefiting from personalized cancer treatments that improve patient outcomes. Cardiovascular and neurology applications are also gaining momentum, reflecting an increasing focus on individualized care. The second highest performing segment is the personalized nutrition and wellness sector, which is expanding as consumers seek customized health solutions. Nutrigenomics and microbiome-based products are at the forefront, offering personalized dietary recommendations and supplements. Genetic testing services are also advancing, providing insights into individual health risks and predispositions. The integration of artificial intelligence and big data analytics is further enhancing the personalization of medical solutions, driving innovation and efficiency across the market.

Market Segmentation
TypeTherapeutics, Diagnostics
ProductPharmacogenomics, Companion Diagnostics, Targeted Therapeutics, Genetic Testing Kits
ServicesGenomic Sequencing, Molecular Diagnostics Services, Personalized Medicine Consultations
TechnologyNext-Generation Sequencing, Polymerase Chain Reaction, Bioinformatics, Gene Editing
ApplicationOncology, Cardiology, Neurology, Infectious Diseases, Respiratory Diseases
End UserHospitals, Clinics, Academic Research Institutions, Pharmaceutical Companies
ComponentSoftware, Hardware, Services
DeviceWearable Devices, Point-of-Care Devices, Laboratory Instruments
ProcessBiomarker Discovery, Drug Development, Clinical Trials
SolutionsIntegrated Platforms, Standalone Solutions, Customized Solutions

Within the Personalized Medicine Market, innovative product launches and strategic pricing strategies are shaping market share dynamics. Companies are focusing on precision-based therapies, creating a competitive landscape driven by technological advancements. The market is witnessing a surge in demand for personalized treatment solutions, particularly in oncology and rare diseases. This trend is encouraging pharmaceutical companies to invest in research and development, fostering a culture of innovation. As a result, the market is experiencing a shift towards more targeted and effective treatment options, enhancing patient outcomes and driving industry growth. Competition benchmarking reveals that key players are intensifying efforts to differentiate through advanced genomics and bioinformatics. Regulatory influences, particularly in the U.S. and Europe, are pivotal in shaping market trajectories, with stringent guidelines ensuring safety and efficacy. The regulatory landscape is fostering innovation while maintaining high standards. Market analysis indicates a robust growth trajectory, driven by technological integration and strategic collaborations. The market is poised for expansion, with digital health technologies and personalized diagnostics offering lucrative opportunities. Challenges remain, including high costs and regulatory complexities, yet the potential for transformative healthcare solutions is immense.

Geographical Overview:

The personalized medicine market is witnessing robust growth across various regions, each presenting unique opportunities. North America leads the market, driven by advanced healthcare infrastructure and substantial investments in genomic research. The region's focus on precision medicine and patient-centric approaches enhances its market position. Europe follows closely, with strong government support and initiatives promoting personalized healthcare solutions. The region's emphasis on innovative healthcare practices fosters a conducive environment for market expansion. In the Asia Pacific, the market is expanding rapidly, propelled by rising healthcare expenditures and increasing awareness of personalized treatment options. Countries like China and India are emerging as key players, investing heavily in biotechnology and genomics. Latin America and the Middle East & Africa are also gaining traction. Brazil and the UAE are recognizing the potential of personalized medicine in improving healthcare outcomes, thus driving investments and fostering growth in these regions.

Global tariffs and geopolitical tensions are recalibrating the Personalized Medicine Market's dynamics, particularly in Japan, South Korea, China, and Taiwan. Japan and South Korea are fortifying their biopharmaceutical sectors, investing in local R&D to mitigate reliance on foreign imports. China is accelerating its indigenous biotech capabilities, driven by export restrictions and a desire for self-reliance. Taiwan, pivotal in precision medicine technologies, navigates geopolitical sensitivities while maintaining its innovation edge. The global market, buoyed by advancements in genomics and diagnostics, is robust, yet susceptible to supply chain disruptions and energy price volatility, exacerbated by Middle East conflicts. By 2035, the market's evolution will hinge on strategic regional collaborations and resilience against geopolitical and economic uncertainties.

Key Trends and Drivers:

The personalized medicine market is experiencing robust growth, propelled by advances in genomics and biotechnology. A significant trend is the integration of artificial intelligence and machine learning in drug development and diagnostics. These technologies enable the identification of biomarkers and the customization of treatment plans, enhancing patient outcomes. Another trend is the rising demand for targeted therapies, driven by the increasing prevalence of chronic diseases and the need for more effective treatments. Personalized medicine offers tailored approaches that improve efficacy and reduce adverse effects. Regulatory bodies are also playing a pivotal role by supporting precision medicine initiatives, which further accelerates market growth. Additionally, the expansion of direct-to-consumer genetic testing services is empowering individuals to make informed health decisions. This trend is complemented by the growing availability of companion diagnostics, which facilitate the selection of suitable therapies. The convergence of digital health technologies and personalized medicine is creating new opportunities for innovation and patient engagement, positioning the market for sustained expansion.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Component
  • 2.8 Key Market Highlights by Device
  • 2.9 Key Market Highlights by Process
  • 2.10 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Therapeutics
    • 4.1.2 Diagnostics
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Pharmacogenomics
    • 4.2.2 Companion Diagnostics
    • 4.2.3 Targeted Therapeutics
    • 4.2.4 Genetic Testing Kits
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Genomic Sequencing
    • 4.3.2 Molecular Diagnostics Services
    • 4.3.3 Personalized Medicine Consultations
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Next-Generation Sequencing
    • 4.4.2 Polymerase Chain Reaction
    • 4.4.3 Bioinformatics
    • 4.4.4 Gene Editing
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Cardiology
    • 4.5.3 Neurology
    • 4.5.4 Infectious Diseases
    • 4.5.5 Respiratory Diseases
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Clinics
    • 4.6.3 Academic Research Institutions
    • 4.6.4 Pharmaceutical Companies
  • 4.7 Market Size & Forecast by Component (2020-2035)
    • 4.7.1 Software
    • 4.7.2 Hardware
    • 4.7.3 Services
  • 4.8 Market Size & Forecast by Device (2020-2035)
    • 4.8.1 Wearable Devices
    • 4.8.2 Point-of-Care Devices
    • 4.8.3 Laboratory Instruments
  • 4.9 Market Size & Forecast by Process (2020-2035)
    • 4.9.1 Biomarker Discovery
    • 4.9.2 Drug Development
    • 4.9.3 Clinical Trials
  • 4.10 Market Size & Forecast by Solutions (2020-2035)
    • 4.10.1 Integrated Platforms
    • 4.10.2 Standalone Solutions
    • 4.10.3 Customized Solutions

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Component
      • 5.2.1.8 Device
      • 5.2.1.9 Process
      • 5.2.1.10 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Component
      • 5.2.2.8 Device
      • 5.2.2.9 Process
      • 5.2.2.10 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Component
      • 5.2.3.8 Device
      • 5.2.3.9 Process
      • 5.2.3.10 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Component
      • 5.3.1.8 Device
      • 5.3.1.9 Process
      • 5.3.1.10 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Component
      • 5.3.2.8 Device
      • 5.3.2.9 Process
      • 5.3.2.10 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Component
      • 5.3.3.8 Device
      • 5.3.3.9 Process
      • 5.3.3.10 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Component
      • 5.4.1.8 Device
      • 5.4.1.9 Process
      • 5.4.1.10 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Component
      • 5.4.2.8 Device
      • 5.4.2.9 Process
      • 5.4.2.10 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Component
      • 5.4.3.8 Device
      • 5.4.3.9 Process
      • 5.4.3.10 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Component
      • 5.4.4.8 Device
      • 5.4.4.9 Process
      • 5.4.4.10 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Component
      • 5.4.5.8 Device
      • 5.4.5.9 Process
      • 5.4.5.10 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Component
      • 5.4.6.8 Device
      • 5.4.6.9 Process
      • 5.4.6.10 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Component
      • 5.4.7.8 Device
      • 5.4.7.9 Process
      • 5.4.7.10 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Component
      • 5.5.1.8 Device
      • 5.5.1.9 Process
      • 5.5.1.10 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Component
      • 5.5.2.8 Device
      • 5.5.2.9 Process
      • 5.5.2.10 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Component
      • 5.5.3.8 Device
      • 5.5.3.9 Process
      • 5.5.3.10 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Component
      • 5.5.4.8 Device
      • 5.5.4.9 Process
      • 5.5.4.10 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Component
      • 5.5.5.8 Device
      • 5.5.5.9 Process
      • 5.5.5.10 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Component
      • 5.5.6.8 Device
      • 5.5.6.9 Process
      • 5.5.6.10 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Component
      • 5.6.1.8 Device
      • 5.6.1.9 Process
      • 5.6.1.10 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Component
      • 5.6.2.8 Device
      • 5.6.2.9 Process
      • 5.6.2.10 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Component
      • 5.6.3.8 Device
      • 5.6.3.9 Process
      • 5.6.3.10 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Component
      • 5.6.4.8 Device
      • 5.6.4.9 Process
      • 5.6.4.10 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Component
      • 5.6.5.8 Device
      • 5.6.5.9 Process
      • 5.6.5.10 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Illumina
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Qiagen
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Myriad Genetics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Genomic Health
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Natera
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Foundation Medicine
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Adaptive Biotechnologies
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Guardant Health
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Invitae
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Personalis
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Care Dx
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Blueprint Medicines
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Blueprint Genetics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Grail
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Freenome
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Sema4
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Tempus
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Caris Life Sciences
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Neo Genomics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Syapse
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us